01Lexicon Pharmaceuticals reported Q3 EPS of -$0.03, beating estimates of -$0.05 by $0.02 per share on November 5, 2026.
02Revenue reached $11.2M, substantially exceeding the $5.5M consensus estimate, representing a 103% beat.
03The stock trades at $1.61 with a market cap of $481.5M after the earnings release.
04Recent quarterly results show volatility, with Q2 missing estimates by 40% while Q3 beat by 40%.
05The company remains unprofitable, with losses in three of the past four quarters despite Q3 outperformance.
Earnings Results
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly earnings results on November 05, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.03, beating the consensus estimate of $-0.05 by $0.02 per share. Revenue came in at $11.2M, beating the estimate of $5.5M.
Company Overview
Lexicon Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $1.61 with a market capitalization of $481.5M.
Lexicon Pharmaceuticals's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 40% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Lexicon Pharmaceuticals should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.